Patents by Inventor John P. McKearn

John P. McKearn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL MONOCLONAL ANTIBODIES TO OSTEOPONTIN
    Publication number: 20190367602
    Abstract: The present disclosure relates to the development of antibodies that are targeted to disease specific function directing regions of osteopontin. Such antibodies are capable of binding osteopontin and of selectively blocking one or more functions of osteopontin. In one aspect, the disclosures are based on the discovery that such antibodies spontaneously occur in certain diseases, and have therapeutic utility for the treatment of one or more osteopontin related diseases, where they are capable of selectively blocking the role of osteopontin in disease progression.
    Type: Application
    Filed: December 12, 2017
    Publication date: December 5, 2019
    Inventors: John P. MCKEARN, Jeremy BLITZER
  • METHODS FOR THE MODULATION OF CRP BY THE SELECTIVE MODULATION OF PPAR DELTA
    Publication number: 20080004281
    Abstract: The present invention discloses methods to reduce C-reactive protein (CRP) in patients in need thereof comprising the selective modulation of PPAR?.
    Type: Application
    Filed: June 26, 2007
    Publication date: January 3, 2008
    Applicant: KALYPSYS, INC.
    Inventors: Tadimeti S. Rao, John P. McKearn, Mausumee Guha
  • Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
    Patent number: 6916800
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: July 12, 2005
    Assignee: Pfizer Inc
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
    Patent number: 6858598
    Abstract: A method of using an MMP inhibitor and optionally radiation therapy, and one or more antineoplastic agents of the topoisomerase class selected from the group consisting of irinotecan and topotecan, as a combination therapy for the treatment of neoplasia is disclosed.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: February 22, 2005
    Assignee: G. D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
    Patent number: 6833373
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: December 21, 2004
    Assignee: G.D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
    Publication number: 20040234624
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.
    Type: Application
    Filed: June 10, 2004
    Publication date: November 25, 2004
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Multi-functional hematopoietic fusion proteins between sequence rearranged G-CSF receptor agonists and other hematopoietic factors
    Publication number: 20040171115
    Abstract: Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.
    Type: Application
    Filed: October 27, 2003
    Publication date: September 2, 2004
    Inventors: Yiqing Feng, Nicholas R. Staten, Charles M. Baum, Neena L. Summers, Maire Helena Caparon, S. Christopher Bauer, Linda L. Zurfluh, John P. McKearn, Barbara K. Klein, Stephen C. Lee, Charles A. McWherter, Judith G. Giri
  • Circular permuteins of flt3 ligand
    Publication number: 20040127410
    Abstract: Disclosed are novel flt-3 receptor agonist proteins, DNAs which encode the flt-3 receptor agonist proteins, methods of making the flt-3 receptor agonist proteins and methods of using the flt-3 receptor agonist proteins.
    Type: Application
    Filed: August 20, 2003
    Publication date: July 1, 2004
    Inventors: Charles A. McWherter, Yiqing Feng, John P. McKearn, Nicholas R. Staten, Philip R. Streeter, Susan L. Woulfe, Nancy I. Minster, John C. Minnerly
  • Fused G-CSF and IL-3 proteins and uses thereof
    Patent number: 6730303
    Abstract: Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: May 4, 2004
    Assignee: Pharmacia Corporation
    Inventors: Yiqing Feng, Nicholas R. Staten, Charles M. Baum, Neena L. Summers, Maire Helena Caparon, S. Christopher Bauer, Linda L. Zurfluh, John P. McKearn, Barbara K. Klein, Stephen C. Lee, Charles A. McWherter, Judith G. Giri
  • Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
    Patent number: 6689787
    Abstract: The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: February 10, 2004
    Assignee: G. D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
    Patent number: 6649645
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a cyclooxygenase-2 inhibitor.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: November 18, 2003
    Assignee: Pharmacia Corporation
    Inventors: John P McKearn, Jaime L Masferrer, Luka Milas
  • Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production
    Publication number: 20030194783
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Application
    Filed: February 8, 2002
    Publication date: October 16, 2003
    Inventors: John P. McKearn, Peter Olins, John Thomas, Maire Caparon, Alan Easton, Barbara Klein, S. Christopher Bauer, Mark Abrams, Kumnan Paik, Sarah Braford-Goldberg
  • Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteins
    Publication number: 20030185790
    Abstract: The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a chimera protein which comprises a variant of human interleukin-3 (hIL-3) which contains multiple amino acid substitutions and which may have portions of the native hIL-3 molecule deleted and a hematopoietic growth factor. The present invention also relates to the ex-vivo expansion of hematopoietic cells for gene therapy. Additionally, the present invention relates to the use of the expanded hematopoietic cells for treating patients having a hematopoietic disorder.
    Type: Application
    Filed: February 26, 2002
    Publication date: October 2, 2003
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Methods of ex-vivo expansion of hematopoeitic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
    Publication number: 20030165461
    Abstract: The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a variant of human interleukin-3 (hIL-3), which contains multiple amino acid substitutions and which may have portions of the native hIL-3 molecule deleted, and a hematopoietic growth factor. The present invention also relates to the ex-vivo expansion of hematopoietic cells for gene therapy. Additionally, the present invention relates to the use of the expanded hematopoietic cells for treating patients having a hematopoietic disorder.
    Type: Application
    Filed: May 13, 2002
    Publication date: September 4, 2003
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Method of ex-vivo expansion of hematopoeitic cells using interleukin-3 (IL-3) multiple mutation polypeptides
    Publication number: 20030103936
    Abstract: The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a variant of human interleukin-3 (hIL-3) which contains multiple amino acid substitutions and which may have portions of the native hIL-3 molecule deleted. The present invention also relates to the ex-vivo expansion of hematopoietic cells for gene therapy. Additionally, the present invention relates to the use of the expanded hematopoietic cells for treating patients having a hematopoietic disorder.
    Type: Application
    Filed: March 4, 2002
    Publication date: June 5, 2003
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
    Patent number: 6451852
    Abstract: A class of substituted phenylacetonitrile-alkylaminoalkyl-ortho-substituted aryl compounds having immunosuppressive properties is described. Compounds of this class would be useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune or inflammatory diseases.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: September 17, 2002
    Assignee: G. D. Searle & Co.
    Inventors: Chi-Dean Liang, John P. McKearn, John M. Farah, Jr., Richard A. Mueller
  • Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 (IL-3) multiple mutation polypeptides
    Patent number: 6440407
    Abstract: The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a variant of human interleukin-3 (hIL-3) which contains multiple amino acid substitutions and which may have portions of the native hIL-3 molecule deleted. The present invention also relates to the ex-vivo expansion of hematopoietic cells for gene therapy. Additionally, the present invention relates to the use of the expanded hematopoietic cells for treating patients having a hematopoietic disorder.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: August 27, 2002
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins
    Patent number: 6436387
    Abstract: The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a chimera protein which comprises a variant of human interleukin-3 (hIL-3) which contains multiple amino acid substitutions and which may have portions of the native hIL-3 molecule deleted and a hematopoietic growth factor. The present invention also relates to the ex-vivo expansion of hematopoietic cells for gene therapy. Additionally, the present invention relates to the use of the expanded hematopoietic cells for treating patients having a hematopoietic disorder.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: August 20, 2002
    Assignee: G.D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Antiangiogenic combination therapy for the treatment of cancer
    Publication number: 20020103141
    Abstract: The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.
    Type: Application
    Filed: April 25, 2001
    Publication date: August 1, 2002
    Inventors: John P. McKearn, Gary B. Gordon, James Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
    Patent number: 6413509
    Abstract: The present invention relates to methods of ex-vivo expansion of hematopoietic cells by culturing hematopoietic cells in a growth medium comprising a variant of human interleukin-3 (hIL-3), which contains multiple amino acid substitutions and which may have portions of the native hIL-3 molecule deleted, and a hematopoietic growth factor. The present invention also relates to the ex-vivo expansion of hematopoietic cells for gene therapy. Additionally, the present invention relates to the use of the expanded hematopoietic cells for treating patients having a hematopoietic disorder.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: July 2, 2002
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John Thomas